Meningococcal B vaccination for gonorrhoea prevention in men who have sex with men – time to revisit the recommendation?

World Health Organization (WHO) estimated that globally 82.4 million new cases of gonorrhoea had occurred in 2020.[1] Emergence of antimicrobial resistance (AMR) is a real concern, and Neisseria gonorrhoeae is again on the WHO Bacterial Priority Pathogens List for AMR research in 2024.[2] For the development of preventive strategy against gonorrhoea, men who have sex with men (MSM) are often targeted because of their being disproportionally affected.[3] Recent evidence suggested that the outer membrane vesicle (OMV) meningococcal B vaccines may provide cross-protection against gonorrhoea.